DE3687402T2 - Thrombinzusammensetzung. - Google Patents
Thrombinzusammensetzung.Info
- Publication number
- DE3687402T2 DE3687402T2 DE8686307922T DE3687402T DE3687402T2 DE 3687402 T2 DE3687402 T2 DE 3687402T2 DE 8686307922 T DE8686307922 T DE 8686307922T DE 3687402 T DE3687402 T DE 3687402T DE 3687402 T2 DE3687402 T2 DE 3687402T2
- Authority
- DE
- Germany
- Prior art keywords
- thrombin
- preparation
- buffer
- range
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 239000000203 mixture Substances 0.000 title claims description 19
- 108090000190 Thrombin Proteins 0.000 claims abstract description 84
- 229960004072 thrombin Drugs 0.000 claims abstract description 79
- 238000002360 preparation method Methods 0.000 claims abstract description 52
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 30
- 239000000872 buffer Substances 0.000 claims abstract description 24
- 229920005862 polyol Polymers 0.000 claims abstract description 10
- 150000003077 polyols Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 229940030225 antihemorrhagics Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000002874 hemostatic agent Substances 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 abstract description 12
- 229920001281 polyalkylene Polymers 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 35
- 239000000243 solution Substances 0.000 description 26
- 235000011187 glycerol Nutrition 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000035602 clotting Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical class [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/22—Blood coagulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/791,836 US4696812A (en) | 1985-10-28 | 1985-10-28 | Thrombin preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3687402D1 DE3687402D1 (de) | 1993-02-11 |
| DE3687402T2 true DE3687402T2 (de) | 1993-05-06 |
Family
ID=25154936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8686307922T Revoked DE3687402T2 (de) | 1985-10-28 | 1986-10-14 | Thrombinzusammensetzung. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4696812A (enExample) |
| EP (1) | EP0221700B1 (enExample) |
| JP (1) | JPH0764747B2 (enExample) |
| KR (1) | KR870003793A (enExample) |
| AT (1) | ATE83927T1 (enExample) |
| AU (1) | AU586897B2 (enExample) |
| CA (1) | CA1272128A (enExample) |
| DE (1) | DE3687402T2 (enExample) |
| DK (1) | DK512686A (enExample) |
| ES (1) | ES2053442T3 (enExample) |
| GR (1) | GR3006727T3 (enExample) |
| NZ (1) | NZ217190A (enExample) |
| PH (1) | PH23444A (enExample) |
| ZA (1) | ZA868223B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965203A (en) * | 1987-01-28 | 1990-10-23 | Warner-Lambert Company | Purified thrombin preparations |
| ZA88227B (en) * | 1987-01-28 | 1988-06-30 | Warner-Lambert Company | Thrombin preparations |
| JPS6440433A (en) * | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
| JP2715104B2 (ja) * | 1988-08-18 | 1998-02-18 | 株式会社ミドリ十字 | トロンビン乾燥製剤 |
| US4891359A (en) * | 1988-12-08 | 1990-01-02 | Johnson & Johnson Patient Care, Inc. | Hemostatic collagen paste composition |
| GB8903438D0 (en) * | 1989-02-15 | 1989-04-05 | May & Baker Ltd | New compositions of matter |
| DK223389D0 (da) * | 1989-05-05 | 1989-05-05 | Ferrosan As | Saarsvamp |
| US5281528A (en) * | 1989-12-18 | 1994-01-25 | Warner-Lambert Company | Process for purified thromboplastin for ultra-pure thrombin preparation |
| US5219328A (en) * | 1990-01-03 | 1993-06-15 | Cryolife, Inc. | Fibrin sealant delivery method |
| US5318524A (en) * | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
| IE73210B1 (en) * | 1990-01-24 | 1997-05-07 | Warner Lambert Co | Process for the production of thrombin and high purity thrombin preparation thereby obtained |
| JPH0813750B2 (ja) * | 1990-03-01 | 1996-02-14 | 持田製薬株式会社 | 経口用トロンビン製剤 |
| US5595735A (en) * | 1990-05-23 | 1997-01-21 | Johnson & Johnson Medical, Inc. | Hemostatic thrombin paste composition |
| ATE143411T1 (de) * | 1991-03-28 | 1996-10-15 | Warner Lambert Co | Hochreine thrombinzubereitung |
| DK83092D0 (da) * | 1992-06-24 | 1992-06-24 | Unes As | Fremgangsmaade til udvinding af thrombin |
| JP3230713B2 (ja) * | 1992-10-23 | 2001-11-19 | トヨタ自動車株式会社 | ピークトルク低減機構 |
| US5795780A (en) * | 1993-06-23 | 1998-08-18 | Bristol-Myers Squibb Company | Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes |
| US5506127A (en) * | 1994-09-21 | 1996-04-09 | Proba; Zbigniew | Therapeutic grade thrombin produced by chromatography |
| WO1997037694A1 (en) * | 1996-04-04 | 1997-10-16 | Immuno Aktiengesellschaft | Hemostatic sponge based on collagen |
| WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
| JP3401162B2 (ja) * | 1996-11-21 | 2003-04-28 | 積水化学工業株式会社 | 血液凝固促進剤及び血液検査用容器 |
| JP3927425B2 (ja) * | 1996-11-21 | 2007-06-06 | 積水化学工業株式会社 | 血液凝固促進剤及び血液検査用容器 |
| JP3927403B2 (ja) * | 1996-11-21 | 2007-06-06 | 積水化学工業株式会社 | 血液凝固促進剤及び血液検査用容器 |
| US6274090B1 (en) | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
| US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
| AU7320300A (en) * | 1999-09-27 | 2001-04-30 | International Reagents Corporation | Means of stabilizing thrombin and compositions |
| DE10012732A1 (de) * | 2000-03-18 | 2001-09-20 | Aventis Behring Gmbh | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
| US8187625B2 (en) * | 2001-03-12 | 2012-05-29 | Boston Scientific Scimed, Inc. | Cross-linked gelatin composition comprising a wetting agent |
| US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| EP1573295A2 (en) | 2002-12-11 | 2005-09-14 | Ferrosan A/S | Gelatine-based materials as swabs |
| US20040243044A1 (en) * | 2003-06-02 | 2004-12-02 | Penegor Stephen A. | Hemostatic wound dressing |
| US7927626B2 (en) * | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| WO2005072700A2 (en) | 2004-01-30 | 2005-08-11 | Ferrosan A/S | Haemostatic sprays and compositions |
| ES2313383T3 (es) * | 2004-06-22 | 2009-03-01 | Zymogenetics, Inc. | Composiciones de trombina. |
| US8021684B2 (en) | 2004-07-09 | 2011-09-20 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
| ATE533491T1 (de) * | 2004-09-21 | 2011-12-15 | Trobio Ab | Stabilisierte protease zusammensetzungen enthaltend eine serinprotease, morpholin-derivate und reversible serinprotease- inhibitoren |
| ES2226587B1 (es) | 2004-10-22 | 2005-12-16 | Probitas Pharma, S.A. | Composicion de trombina estable. |
| US7341392B2 (en) * | 2005-04-22 | 2008-03-11 | Dofair Co., Ltd. | Lock device in an articulated joint for a foldable ladder |
| BRPI0711900C1 (pt) * | 2006-05-26 | 2021-05-25 | Baxter Healthcare Sa | sistema de múltiplos componentes para uma composição de enchimento de vazio ósseo injetável, composição injetável de enchimento de vazio ósseo, e, método para preencher um vazio em um osso em um paciente que sofre de um distúrbio ósseo |
| PL2029184T3 (pl) * | 2006-05-26 | 2011-08-31 | Baxter Int | Wstrzykiwalna kompozycja do augmentacji kości |
| RU2009127718A (ru) * | 2006-12-19 | 2011-01-27 | Ферросан А/С (Dk) | Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии |
| WO2008075455A1 (ja) | 2006-12-21 | 2008-06-26 | Sekisui Medical Co., Ltd. | トロンビン含有溶液中のα－トロンビンの安定化方法 |
| PL2136852T3 (pl) * | 2007-03-26 | 2012-07-31 | Baxter Int | Wstrzykiwalny wypełniacz pustych przestrzeni do augmentacji tkanek miękkich |
| US8071090B2 (en) * | 2007-06-15 | 2011-12-06 | Zymogenetics, Inc. | Stabilized thrombin compositions |
| US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| US10046081B2 (en) | 2008-04-11 | 2018-08-14 | The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. | Electrospun dextran fibers and devices formed therefrom |
| CA2721335A1 (en) * | 2008-04-16 | 2009-10-22 | Ryoichi Kawamura | Process for preparing bioabsorbable sheet preparation holding thrombin |
| JP6241624B2 (ja) | 2012-03-06 | 2017-12-06 | フェロサン メディカル デバイシーズ エイ／エス | 止血ペーストを収容する加圧容器 |
| CA2874290C (en) | 2012-06-12 | 2020-02-25 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US9149529B2 (en) | 2012-10-24 | 2015-10-06 | Orthovita, Inc. | Stable compositions containing thrombin and methods for preparation and use thereof |
| CA2912357C (en) | 2013-06-21 | 2019-12-31 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| CN105828844B (zh) | 2013-12-11 | 2019-09-27 | 弗罗桑医疗设备公司 | 包含挤出增强剂的干组合物 |
| EP3206726B1 (en) | 2014-10-13 | 2020-05-27 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| BR112017013565B1 (pt) | 2014-12-24 | 2021-12-28 | Ferrosan Medical Devices A/S | Seringa para retenção e mistura de primeira e segunda substâncias |
| CN104569446A (zh) * | 2015-02-04 | 2015-04-29 | 上海长岛生物技术有限公司 | 一种液体型凝血酶时间检测试剂及其制备方法 |
| CN104630325B (zh) * | 2015-02-04 | 2018-03-02 | 上海长岛生物技术有限公司 | 一种液体型纤维蛋白原检测试剂及其制备方法 |
| CA2986981A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| EP3373853A4 (en) | 2015-11-12 | 2019-07-10 | St. Teresa Medical, Inc. | METHOD FOR SEALING A DUROTOMY |
| US10953128B2 (en) | 2017-11-02 | 2021-03-23 | St. Teresa Medical, Inc. | Fibrin sealant products |
| CN112368028A (zh) | 2018-05-09 | 2021-02-12 | 弗罗桑医疗设备公司 | 用于制备止血组合物的方法 |
| IL261190A (en) | 2018-08-16 | 2019-01-31 | Omrix Biopharmaceuticals Ltd | Stable liquid preparations of thrombin |
| IL262716A (en) * | 2018-11-01 | 2018-11-29 | Omrix Biopharmaceuticals Ltd | Oxidized cellulose preparations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2433299A (en) * | 1944-01-22 | 1947-12-23 | Parke Davis & Co | Blood coagulant and method of preserving same |
| US2532348A (en) * | 1946-12-12 | 1950-12-05 | Szent-Gyorgyi Albert | Blood clotting preparation |
| JPS536483A (en) * | 1976-07-02 | 1978-01-20 | Tanabe Seiyaku Co Ltd | Composition having enzymatic activity and its preparation |
| JPS5639782A (en) * | 1979-09-04 | 1981-04-15 | Dai Ichi Pure Chem Co Ltd | Stabilization of thrombin |
| US4363319A (en) * | 1980-06-30 | 1982-12-14 | Applied Medical Devices, Inc. | Ready-to-use bandage incorporating a coagulant composition and method of preparing same |
| JPS628137A (ja) * | 1985-07-05 | 1987-01-16 | Konishiroku Photo Ind Co Ltd | 情報記録装置 |
-
1985
- 1985-10-28 US US06/791,836 patent/US4696812A/en not_active Expired - Fee Related
-
1986
- 1986-08-13 NZ NZ217190A patent/NZ217190A/xx unknown
- 1986-10-14 DE DE8686307922T patent/DE3687402T2/de not_active Revoked
- 1986-10-14 EP EP86307922A patent/EP0221700B1/en not_active Expired - Lifetime
- 1986-10-14 AT AT86307922T patent/ATE83927T1/de not_active IP Right Cessation
- 1986-10-14 ES ES86307922T patent/ES2053442T3/es not_active Expired - Lifetime
- 1986-10-16 PH PH34377A patent/PH23444A/en unknown
- 1986-10-27 KR KR1019860008973A patent/KR870003793A/ko not_active Abandoned
- 1986-10-27 CA CA000521494A patent/CA1272128A/en not_active Expired - Fee Related
- 1986-10-27 JP JP61253900A patent/JPH0764747B2/ja not_active Expired - Lifetime
- 1986-10-27 DK DK512686A patent/DK512686A/da not_active Application Discontinuation
- 1986-10-28 AU AU64517/86A patent/AU586897B2/en not_active Ceased
- 1986-10-28 ZA ZA868223A patent/ZA868223B/xx unknown
-
1992
- 1992-12-31 GR GR920403095T patent/GR3006727T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR870003793A (ko) | 1987-05-04 |
| JPH0764747B2 (ja) | 1995-07-12 |
| EP0221700B1 (en) | 1992-12-30 |
| ES2053442T3 (es) | 1994-08-01 |
| ZA868223B (en) | 1987-07-29 |
| DE3687402D1 (de) | 1993-02-11 |
| DK512686D0 (da) | 1986-10-27 |
| PH23444A (en) | 1989-08-07 |
| US4696812A (en) | 1987-09-29 |
| JPS62106028A (ja) | 1987-05-16 |
| NZ217190A (en) | 1989-05-29 |
| AU586897B2 (en) | 1989-07-27 |
| EP0221700A3 (en) | 1987-08-26 |
| CA1272128A (en) | 1990-07-31 |
| DK512686A (da) | 1987-04-29 |
| GR3006727T3 (enExample) | 1993-06-30 |
| ATE83927T1 (de) | 1993-01-15 |
| AU6451786A (en) | 1987-04-30 |
| EP0221700A2 (en) | 1987-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3687402T2 (de) | Thrombinzusammensetzung. | |
| US4965203A (en) | Purified thrombin preparations | |
| DE69433133T2 (de) | Lösliches thrombomodulin enthaltende zubereitung | |
| US3868358A (en) | Protamine-insulin product | |
| EP0244834B1 (de) | Verfahren zur Herstellung eines Faktor V-Konzentrats | |
| DE69729786T2 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| DE69333928T2 (de) | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes | |
| AT397203B (de) | Gewebeklebstoff | |
| EP1131110B1 (de) | Stabilisierte proteinzubereitungen für einen gewebekleber | |
| EP0478827B1 (de) | Stabilisiertes Thrombin, seine Herstellung und seine Verwendung als Thrombinzeitreagens | |
| DE3686410T2 (de) | Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens. | |
| EP1136084B1 (de) | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung | |
| DE3872534T2 (enExample) | ||
| DE69630291T2 (de) | Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält | |
| EP1572229B1 (de) | Stabiles therapeutisches fibrinogen | |
| DE2917899A1 (de) | Lyophilisierte urokinasezubereitung zu injektionszwecken und verfahren zu ihrer herstellung | |
| DD289470A5 (de) | Verfahren zur herstellung eines arzneimittels mit einem gehalt an gamma-interferon | |
| EP1221479B1 (en) | Method for stabilizing thrombin | |
| DE69425581T2 (de) | Methode zur stabilisierung von protein c oder aktiviertem protein c und stabilisierte verbindungen | |
| EP3538898B1 (de) | Prothrombinzeit-reagenz enthaltend einen eisenchelator | |
| DE69101784T2 (de) | Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor. | |
| DE69001110T2 (de) | Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon. | |
| CA1289472C (en) | Tpa-containing medical composition | |
| EP0458929B1 (de) | t-PA-Solubilisierung | |
| DE69003061T2 (de) | Protein enthaltende wässerige Lösungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |